The UK’s Medicines and Healthcare products Regulatory Agency has warned that some patients may have been dispensed fake Mounjaro (tirzepatide) KwikPen 15mg pre-filled pens from The Private Pharmacy Clinic in Birmingham. MHRA said all affected fake pens identified so far are 15mg pens with batch number D873576.
The agency also noted an important detail: D873576 is a legitimate batch number for genuine Mounjaro KwikPen 7.5mg, and those genuine 7.5mg pens are not impacted. That distinction matters because it shows how counterfeit or falsified product incidents can exploit real batch information, making visual checks more complicated for patients and pharmacy teams.
MHRA advised patients to check the batch number and strength of their pen and to stop using the affected pen immediately if they have one. The agency said tested fake pens did contain tirzepatide, but because the manufacturing conditions are unknown, it cannot confirm that the contents are sterile. It also said that, based on cases reviewed so far, the risk to people who have already injected from an affected pen appears low.
This is a significant pharmacovigilance story because it sits at the intersection of product quality, supply chain integrity, patient safety, and real-world risk communication. Not every safety issue begins with a classical adverse reaction. Some start with a question about whether the product in the patient’s hand is authentic, sterile, or produced under appropriate conditions. In those cases, pharmacovigilance overlaps closely with quality systems, complaints handling, and regulator communication. That inference is well supported by MHRA’s focus on unknown manufacturing conditions and patient advice.
The incident also reflects the wider pressure surrounding high-demand GLP-1 medicines. Products with strong public demand can attract misuse, diversion, falsification, and unsafe supply pathways. For PV teams, that means postmarketing vigilance cannot be limited to classical case processing alone. The broader product environment can become part of the safety picture.
Why this matters for PV professionals
The fake Mounjaro warning shows that PV teams need to stay alert not only to adverse events, but also to quality defects, falsified medicines, and unsafe distribution patterns that can create indirect or direct patient harm.
0 Comments